Cell Reports · 2016 · 132 citations · 46 references
Life SciencesMolecular BiologyOncologyGene ExpressionTranscriptionTranscriptional RegulationEnhancer FunctionNuclear ReceptorsRna Polymerase FunctionRna Polymerase Ii TranscriptionRna-binding ProteinsSteroid Hormone SignalingAndrogen ReceptorsEnhancer RnasEnhancersP-tefb RegulationRna Polymerase Ii ActivationRna Polymerase Ii FunctionRna Polymerase Ii RegulationSerine Phosphorylation
The androgen receptor (AR) is required for castration-resistant prostate cancer (CRPC) progression, but the function and disease relevance of AR-bound enhancers remain unclear. Here, we identify a group of AR-regulated enhancer RNAs (e.g., PSA eRNA) that are upregulated in CRPC cells, patient-derived xenografts (PDXs), and patient tissues. PSA eRNA binds to CYCLIN T1, activates P-TEFb, and promotes cis and trans target gene transcription by increasing serine-2 phosphorylation of RNA polymerase II (Pol II-Ser2p). We define an HIV-1 TAR RNA-like (TAR-L) motif in PSA eRNA that is required for CYCLIN T1 binding. Using TALEN-mediated gene editing we further demonstrate that this motif is essential for increased Pol II-Ser2p occupancy levels and CRPC cell growth. We have uncovered a P-TEFb activation mechanism and reveal altered eRNA expression that is related to abnormal AR function and may potentially be a therapeutic target in CRPC.
46
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2012 · 4.6K citations · Full text
Medicine, Oncology, Pharmacology +14
Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells
Laurie A. Boyer, Tong Ihn Lee, Megan F. Cole et al. · Cell · 2005 · 4.5K citations · Full text
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. de Bono, Christopher J. Logothetis, Arturo Molina et al. · New England Journal of Medicine · 2011 · 4.4K citations · Full text
Medicine, Oncology, Pharmacology +17
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis, Changxue Lu, Hao Wang et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Oncology, Pharmacology +17
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al. · Nature · 2012 · 2.6K citations